Telix Total Current Assets from 2010 to 2024

TLX Stock   15.76  0.16  1.03%   
Telix Pharmaceuticals Total Current Assets yearly trend continues to be fairly stable with very little volatility. Total Current Assets will likely drop to about 148.3 M in 2024. Total Current Assets is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. View All Fundamentals
 
Total Current Assets  
First Reported
2010-12-31
Previous Quarter
224.8 M
Current Value
148.3 M
Quarterly Volatility
42.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 1.1 M, Depreciation And Amortization of 7.1 M or Interest Expense of 7.1 M, as well as many indicators such as Price To Sales Ratio of 0.41, Days Sales Outstanding of 45.23 or Average Payables of 1.8 M. Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Telix Pharmaceuticals Correlation against competitors.

Latest Telix Pharmaceuticals' Total Current Assets Growth Pattern

Below is the plot of the Total Current Assets of Telix Pharmaceuticals Limited over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Telix Pharmaceuticals' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Telix Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Total Current Assets10 Years Trend
Slightly volatile
   Total Current Assets   
       Timeline  

Telix Total Current Assets Regression Statistics

Arithmetic Mean108,255,087
Geometric Mean101,924,736
Coefficient Of Variation39.39
Mean Deviation29,548,005
Median93,628,000
Standard Deviation42,643,540
Sample Variance1818.5T
Range177.3M
R-Value0.52
Mean Square Error1432.4T
R-Squared0.27
Significance0.05
Slope4,941,675
Total Sum of Squares25458.6T

Telix Total Current Assets History

2024148.3 M
2023224.8 M
2022173.2 M
202147.5 M

About Telix Pharmaceuticals Financial Statements

Telix Pharmaceuticals investors use historical fundamental indicators, such as Telix Pharmaceuticals' Total Current Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Telix Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Current Assets224.8 M148.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.